AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and Processes
OrchiectomyProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsAndrogen AntagonistsReceptors, AndrogenCastrationCell Line, TumorProstateTaxoidsAndrogensDrug Resistance, NeoplasmProstate-Specific AntigenTestosteroneProstatectomyNeoplasms, Hormone-DependentProstatic HyperplasiaGene Expression Regulation, NeoplasticDihydrotestosteroneTosyl CompoundsMice, NudeAdenocarcinomaNeoplasm MetastasisEarly Detection of CancerDisease ProgressionTumor Markers, BiologicalFlutamideAndrogen Receptor AntagonistsApoptosisProstatic Intraepithelial NeoplasiaAntineoplastic Agents, HormonalAnilidesBone NeoplasmsAntineoplastic AgentsCell ProliferationTumor Cells, CulturedSeminal Vesicles
AntigenMCRPC2023ChemotherapyEnzalutamideSolid tumorsClinically Localized Prostate CancerSymptomaticTumorsColorectalCastrate-resistantNonmetastaticAbirateroneSurvivalOvarianMetastasesRadiotherapy for localized prostate cancerImmunotherapyPatients with prostate cancerDiagnosisClinical TrialsOutcomesGastric cancerBiopsyBoneLocallyAsymptomaticStage 4 prostate cancerMalignanciesApalutamideTestosteroneCRPCProgressionCabazitaxelPSMATherapyOncologyProstaticRecurrentRefractoryMitoxantroneDetectionTumor growthMethylprednisoloneAbstractAndrogen suppressionTherapiesVariantsPrognosticFindingsHereditaryDiseaseBreast cancersScreeningInhibitorBiopsiesMortality
Antigen19
  • METHODS: We evaluated toxicity, overall survival (OS), progression-free survival (PFS) and time to prostate-specific antigen (PSA) progression data from 47 CRPC patients treated with fourth- or fifth-line Enz. (ru.nl)
  • The drug candidate is a bi-specific T cell engager (TCE) which acts by targeting cells expressing prostate specific membrane antigen (PSMA) and T cells. (globaldata.com)
  • Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. (ambrx.com)
  • Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. (journalsmededu.pl)
  • Patients who had no prostate-specific antigen (PSA) response or had no evidence of radiographic progression were not eligible for period 2, during which 273 patients remained and were randomized (1:1) to enzalutamide 160 mg daily, or to placebo. (jhoponline.com)
  • Prostate-specific antigen (PSA)-levels, changes in PSMA-uptake of MLN metastases and further 68 Ga-PSMA PET/CT findings were recorded. (frontiersin.org)
  • The Type-II transmembrane protein prostate specific membrane antigen (PSMA) is overexpressed in almost all PCa cells ( 6 ). (frontiersin.org)
  • Participants will undergo regular testing for signs of disease progression using computed tomography (CT) scans, magnetic resonance imaging (MRI), bone scans, and prostate-specific antigen (PSA) blood tests. (uclahealth.org)
  • City of Hope's comprehensive chimeric antigen receptor (CAR) T cell therapy program is addressing some of the hardest-to-treat cancers by accelerating innovative clinical research approaches. (cityofhope.org)
  • In prostate cancer, whole-body PET determinations of prostate-specific membrane antigen (PSMA) expression are now established, approved, and available for disease staging and restaging. (snmjournals.org)
  • Bristol-Myers Squibb has signed an exclusive option to license and commercialize PROSTVAC, Bavarian Nordic 's investigational phase III prostate-specific antigen (PSA)-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). (centerwatch.com)
  • Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation. (cgmh.org.tw)
  • Men with high-grade prostate cancer and low prostate-specific antigen (PSA) levels have a poor prognosis. (news-medical.net)
  • PET using 68Ga prostate-specific membrane antigen 11 (68Ga-PSMA) is a promising tool for response evaluation of mCRPC. (bvsalud.org)
  • The guidelines differ in their recommendations regarding whether or not to provide routine prostate-specific antigen (PSA)-based prostate cancer screening, in what age groups and life expectancies, and at what intervals. (medscape.com)
  • The current recommendations of the AUA date from 2013 and update the Association's 2009 Best Practice Statement on Prostate-Specific Antigen (PSA). (medscape.com)
  • Diagnosis is suggested by digital rectal examination (DRE) or prostate-specific antigen (PSA) measurement and confirmed by transrectal ultrasound-guided biopsy. (msdmanuals.com)
  • Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: A meta-analysis. (msdmanuals.com)
  • Background: In prostate cancer (PCa), questions remain on indications for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging and PSMA radioligand therapy, integration of advanced imaging in nomogram-based decision-making, dosimetry, and development of new theranostic applications. (lu.se)
MCRPC38
  • Treatment with docetaxel in combination with prednisone is the standard first-line treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). (urotoday.com)
  • The outcome in routine daily clinical practice of a cohort of unselected chemotherapy-naïve mCRPC patients treated with docetaxel plus methylprednisolone as first- and further-line treatment in a single institution was investigated. (urotoday.com)
  • OBJECTIVE: To evaluate the efficacy of enzalutamide (Enz) as fourth- or fifth-line treatment in men with metastasized castration-resistant prostate cancer (mCRPC), by analyzing a retrospective cohort of heavily pretreated patients. (ru.nl)
  • Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen. (aihta.at)
  • cancer (mCRPC). (facingourrisk.org)
  • This clinical trial may be an option for you if you have been diagnosed with mCRPC that has spread or gotten worse since your last treatment. (facingourrisk.org)
  • JANX-007 is under development for the treatment of metastatic castration resistant prostate cancer (mCRPC). (globaldata.com)
  • SAN DIEGO, July 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the "Company") (NASDAQ: AMAM), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ambrx's proprietary anti-PSMA antibody-drug conjugate (ADC) investigational therapy, ARX517, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) upon progression on an androgen receptor pathway inhibitor. (ambrx.com)
  • Receiving Fast Track designation from the FDA reinforces Ambrx's belief in ARX517 as a potential novel treatment for mCRPC and underscores the urgent need for improved treatment options for patients at this advanced stage of prostate cancer," said Sandra Aung, Ph.D., Chief Clinical Officer of Ambrx. (ambrx.com)
  • In January 2022, Hinova Pharmaceuticals announced that the first patient with metastatic castration-resistant prostate cancer (mCRPC) had been successfully dosed in Phase I clinical trial of HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR). (giridihjournal.in)
  • In May 2022, Janux Therapeutics announced that the US Food and Drug Administration (FDA) cleared the Company's investigational new drug (IND) application for its lead product candidate, JANX007, a PSMA-TRACTr in development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). (giridihjournal.in)
  • In patients with metastatic castration-resistant prostate cancer (mCRPC), overall survival (OS) is markedly enhanced with cabazitaxel versus mitoxantrone after prior docetaxel treatment. (wikipedia.org)
  • The Food and Drug Administration (FDA) has approved Lynparza ® (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adults with deleterious or suspected deleterious BRCA -mutated metastatic castration-resistant prostate cancer (mCRPC). (empr.com)
  • The PROpel results showed the Lynparza combination demonstrated a notable clinically meaningful benefit that should rapidly be considered as the standard of care treatment for patients with BRCAm mCRPC. (empr.com)
  • Lynparza , a poly (ADP-ribose) polymerase (PARP) inhibitor, is also approved for the treatment of adults with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC who have progressed following prior treatment with enzalutamide or abiraterone. (empr.com)
  • monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). (stockhouse.com)
  • In the U.S., prostate cancer is the second most common cancer in men, and despite an increase in the number of available therapies for patients with mCRPC, five-year survival remains low. (yahoo.com)
  • Dave Fredrickson, executive vice president, oncology business unit, AstraZeneca, said, 'There is a critical unmet need for new first-line treatment options for patients with BRCA m mCRPC, and this approval underscores the importance of BRCA testing at metastatic diagnosis. (yahoo.com)
  • The study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor axis-targeted therapy (ARAT). (uclahealth.org)
  • The treatment combination of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) demonstrated significant improvements regarding survival without disease progression for patients with metastatic castration-resistant prostate cancer (mCRPC), according to preliminary results from a phase 3 trial. (curetoday.com)
  • Patients with mCRPC also tend to have a poor prognosis, in which survival is estimated to be one to two years, as reported in the journal Clinical Genitourinary Cancer . (curetoday.com)
  • According to a press release from biotechnology company Exelixis Inc. and biopharmaceutical company Ipsen, the phase 3 trial CONTACT-02 is currently evaluating Cabometyx plus Tecentriq compared with a novel hormonal therapy as treatment for patients with mCRPC and measurable soft tissue disease who have been previously treated with one novel hormonal therapy. (curetoday.com)
  • The US Food and Drug Administration (FDA) has approved the Janssen Pharmaceutical Companies of Johnson & Johnson's AKEEGA for treating patients with metastatic castration-resistant prostate cancer (mCRPC). (pharmaceutical-technology.com)
  • It is indicated with prednisone to treat adults with mCRPC and BRCA[a specific cancer gene]-positive mutations. (pharmaceutical-technology.com)
  • This milestone, which marks the approval of Janssen's third prostate cancer treatment, highlights the importance of advancing precision medicine approaches and genetic testing for the treatment of patients with BRCA-positive mCRPC. (pharmaceutical-technology.com)
  • Belinostat is under clinical development by Acrotech Biopharma and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). (pharmaceutical-technology.com)
  • According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. (pharmaceutical-technology.com)
  • SEAL BEACH, Calif.-( BUSINESS WIRE )-Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, today announced publication of results from its PROCEED registry, which evaluated real-world use of PROVENGE ® (sipuleucel-T) in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC). (gabio.org)
  • Of those, 95% were treated with PROVENGE as first-line therapy for mCRPC as recommended by the National Comprehensive Cancer Network (NCCN). (gabio.org)
  • PROCEED enrolled 1,976 patients with mCRPC who received PROVENGE between 2011 and 2014 in everyday treatment settings. (gabio.org)
  • With metastatic castration-resistant prostate cancer (mCRPC), or hormone-refractory prostate cancer, your current therapy is no longer effective in controlling the disease. (everydayhealth.com)
  • NEW YORK, November 13, 2023 - Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. (pfizer.com)
  • AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with 212Pb-ADVC001, a Targeted Alpha Therapy in development for the treatment of PSMA-positive metastatic Castration-Resistant Prostate Cancer (mCRPC). (news-medical.net)
  • CT and bone scintigraphy are not useful for response evaluation of bone metastases to 223Ra treatment in metastatic castration-resistant prostate cancer (mCRPC). (bvsalud.org)
  • The aim of this study was to determine the utility of 68Ga-PSMA PET/CT for response evaluation of 223Ra treatment in patients with mCRPC. (bvsalud.org)
  • Methods: Within this prospective, multicenter, imaging discovery study, 28 patients with mCRPC, eligible for 223Ra treatment, were included between 2019 and 2022. (bvsalud.org)
  • Conclusion: mCRPC patients with lower TTVbone on 68Ga-PSMA PET/CT have the best clinical outcome after 223Ra treatment. (bvsalud.org)
  • Genomic alterations in DNA damage response (DDR) genes are common in metastatic castration-resistant prostate cancer (mCRPC). (cdc.gov)
20232
  • What are the treatment options for metastatic castration-resistant prostate cancer anno 2023? (bjmo.be)
  • DelveInsight's, "Metastatic Castration-Resistant Prostate Cancer Pipeline Insight, 2023," report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer pipeline landscape. (giridihjournal.in)
Chemotherapy11
  • Hormone therapy is a treatment option for advanced prostate cancer, as are chemotherapy and immunotherapy . (medicalnewstoday.com)
  • For people who were treated with anthracyclines - a class of chemotherapy drugs - for childhood cancers, heart failure can be a devastating side effect that develops later in life. (wkrn.com)
  • Sentinel Lymph Node Biopsy After Breast Cancer Chemotherapy This article reviews current evidence for the use of sentinel lymph node biopsy in breast cancer patients who received neoadjuvant chemotherapy. (medscape.com)
  • Patients with metastatic castration-resistant prostate cancer face a poor prognosis of less than two years, and many who progress on a novel hormonal therapy are seeking alternative treatment options to chemotherapy," said Dr. Vicki L. Goodman, executive vice president, product development and medical affairs and chief medical officer of Exelixis, in the press release. (curetoday.com)
  • Prior chemotherapy treatment for castration-sensitive or castration-resistant prostate cancer (docetaxel or cabazitaxel). (orlandohealth.com)
  • Increased survival with enzalutamide in prostate cancer after chemotherapy. (sfu.ca)
  • Abiraterone in metastatic prostate cancer without previous chemotherapy. (sfu.ca)
  • Enzalutamide in metastatic prostate cancer before chemotherapy. (sfu.ca)
  • Chemotherapy may be most effective at controlling metastatic prostate cancer when it's received as an initial treatment, rather than when the cancer becomes resistant to hormone therapy. (everydayhealth.com)
  • Advanced metastatic prostate cancer can be treated with hormone therapy, chemotherapy, immunotherapy, and others, to help you live a longer, better life. (everydayhealth.com)
  • If some of the men being treated did indeed have metastatic disease, we have to consider whether they would benefit best from apalutamide or enzalutamide, or if giving them chemotherapy would be a better approach. (medscape.com)
Enzalutamide10
  • Continuous treatment with the androgen receptor inhibitor enzalutamide, in combination with docetaxel, significantly improved progression-free survival (PFS) compared with placebo plus docetaxel in men with metastatic castration-resistant prostate cancer whose disease progressed while receiving enzalutamide alone in the phase 3b PRESIDE clinical trial. (jhoponline.com)
  • The investigators hypothesized that continuous treatment with enzalutamide may help maintain control of responsive tumor lesions and may allow the addition of docetaxel to target pathways that enhance tumor growth. (jhoponline.com)
  • In addition, enzalutamide treatment delayed the time to PSA progression (8.4 months vs 6.2 months with placebo). (jhoponline.com)
  • These data suggest that continued treatment with enzalutamide plus docetaxel offers a clinical benefit and could be a future treatment option for some patients who progress on enzalutamide alone," said Dr Merseburger. (jhoponline.com)
  • Serious treatment-emergent adverse events were observed in 49.3% of patients who received enzalutamide versus 38.5% of the patients who received placebo. (jhoponline.com)
  • and those who demonstrate fitness for combination therapy should be considered for continuous enzalutamide combination therapy, said Elisabeth I. Heath, MD, FACP, Hartmann Endowed Chair for Prostate Cancer Research, Karmanos Cancer Institute, Detroit, MI. (jhoponline.com)
  • The addition of docetaxel in men who are progressing on enzalutamide is a treatment option due to an increase in PFS in men with metastatic castration-resistant prostate cancer," Dr Heath said. (jhoponline.com)
  • Previous treatment with next-generation androgen receptor (AR)-directed therapy (e.g. abiraterone, enzalutamide, apalutamide, darolutamide). (orlandohealth.com)
  • Must have been administered ARAT (abiraterone, enzalutamide, darolutamide, or apalutamide) in the castration-sensitive or castration-resistant setting. (orlandohealth.com)
  • In the homologous recombination repair-deficient population of TALAPRO-2, a placebo-controlled phase 3 trial, treatment of patients with metastatic castration-resistant prostate cancer with the poly(ADP-ribose) polymerase inhibitor talazoparib plus enzalutamide led to prolonged progression-free survival compared with placebo plus enzalutamide. (nature.com)
Solid tumors3
  • Research on a heart medication for childhood cancer survivors and new immunotherapies for blood and solid tumors will be presented. (wkrn.com)
  • Whether it's working on our own immunotherapy trials for solid tumors, or partnering with companies to find novel medicines, City of Hope is committed to transforming cancer care for our patients and beyond. (wkrn.com)
  • More than 30 company-sponsored abstracts have been accepted, supporting the data from clinical development programs investigating innovative treatments for prostate cancer, hematologic malignancies and solid tumors. (jnj.com)
Clinically Localized Prostate Cancer1
Symptomatic1
  • PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer. (gabio.org)
Tumors3
  • Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine. (thieme-connect.de)
  • Tumors detected and diagnosed early have a favorable prognosis if treated with a complete or en-bloc excision. (medscape.com)
  • The 2016 World Health Organization classification provides a comprehensive listing of prostate tumors, including acinar adenocarcinoma subtypes. (medscape.com)
Colorectal6
  • Ultra-Processed Food and Colorectal Cancer: Is There a Link? (medscape.com)
  • A diet high in ultra-processed foods could lead to negative health effects, but could it also raise the risk of colorectal cancer? (medscape.com)
  • In an arm of a phase 1b trial, the combination of divarasib, a KRAS G12C inhibitor, and cetuximab, an epidermal growth factor receptor inhibitor, was well tolerated with an encouraging overall response rate of 62.5% in patients with KRA S G12C -positive colorectal cancer. (nature.com)
  • The US NCCN guidelines recommend that all, or a high proportion of, patients with a personal history of breast, ovarian, endometrial, pancreatic, colorectal, and prostate cancer should undergo germline testing. (cdc.gov)
  • Lynch Syndrome Lynch syndrome is an autosomal dominant disorder responsible for 2 to 3% of cases of colorectal cancer ( 1). (msdmanuals.com)
  • Symptoms, initial diagnosis, and treatment are similar to other forms of colorectal. (msdmanuals.com)
Castrate-resistant1
  • This disease state is now subdivided into castrate-sensitive or castrate-resistant locally recurrent prostate cancer and castrate-sensitive or castrate-resistant metastatic prostate cancer. (medscape.com)
Nonmetastatic2
  • With nonmetastatic castration-resistant prostate cancer, the prostate cancer no longer responds to hormone therapy, also known as androgen deprivation therapy. (everydayhealth.com)
  • Today's topic is a new antiandrogen for the treatment of men with nonmetastatic, castration-resistant prostate cancer . (medscape.com)
Abiraterone11
  • For some years, docetaxel was the mainstay of treatment in CRPC, but recently, cabazitaxel (a microtubule inhibitor), sipuleucel-T (a cancer vaccine), and abiraterone acetate (a CYP17 inhibitor) were approved for CRPC treatment. (touchoncology.com)
  • FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA -mutated metastatic castration-resistant prostate cancer. (empr.com)
  • Lynparza plus abiraterone approved in the US for the treatment of BRCA -mutated metastatic castration-resistant prostate cancer. (empr.com)
  • Poorer response to treatment of metastatic castration-resistant prostate cancer by AA/P ( abiraterone acetate plus prednisone ). (snpedia.com)
  • Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. (snpedia.com)
  • Abiraterone and increased survival in metastatic prostate cancer. (sfu.ca)
  • Abiraterone for prostate cancer not previously treated with hormone therapy. (sfu.ca)
  • Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. (sfu.ca)
  • Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. (sfu.ca)
  • Has disease that progressed during or after treatment with one next-generation hormonal agent (NHA) for hormone sensitive prostate cancer (HSPC) metastatic hormone sensitive prostate cancer (mHSPC) or non metastatic hormone sensitive prostate cancer (nmHSPC), for at least 8 weeks (at least 14 weeks for participants with bone progression) Note: Participants may have received abiraterone acetate and docetaxel or darolutamide and docetaxel for HSPC. (who.int)
  • If patients progressed, they could receive secondary treatment with abiraterone acetate and prednisone. (medscape.com)
Survival23
  • Normalisation of PSA during first-line treatment with docetaxel is associated with a better survival irrespective of second- or further-line treatment used. (urotoday.com)
  • While the five-year survival rate for men with advanced prostate cancer has increased from 69 % in the late 1970s to 100 % in the 2000s, 2 there have traditionally been no successful treatments that improved median overall survival in the subset of patients with CRPC. (touchoncology.com)
  • In the last decade, however, since the approval of docetaxel by the US Food and Drug Administration (FDA) for metastatic CRPC in 2004, 3 there has been a substantial evolution in its treatment, as several drugs introduced in quick succession show efficacy in prolonging survival. (touchoncology.com)
  • Apalutamide and Overall Survival in Prostate Cancer. (journalsmededu.pl)
  • In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival was 15.1 months for patients receiving cabazitaxel versus 12.7 months for patients receiving mitoxantrone. (wikipedia.org)
  • The primary endpoint was radiological progression free survival (rPFS), defined as the time from randomization to radiological progression, as assessed by investigator per RECIST 1.1 and Prostate Cancer Working Group (PCWG3) (bone) criteria. (empr.com)
  • ICI-Induced Arthralgia Improves Survival in Cancer Patients To what extent is ICI-induced arthralgia associated with overall survival in cancer patients? (medscape.com)
  • Treatment with Cabometyx plus Tecentriq improved progression-free survival for patients with metastatic castration-resistant prostate cancer. (curetoday.com)
  • Preliminary findings from the trial established that the use of Cabometyx combined with Tecentriq has demonstrated a significant improvement in progression-free survival (PFS), defined as the period during and after treatment of cancer when the disease does not worsen, during the primary analysis. (curetoday.com)
  • Researchers also assessed overall survival (the period from diagnosis or treatment where patients are still alive), in which Exelixis noted that a trend toward improvement was observed, but the data were not yet of statistical significance. (curetoday.com)
  • The VISION trial showed that PSMA-targeted molecular radiotherapy (MRT) can prolong survival and improve quality of life of patients with advanced metastatic castration-resistant prostate cancer ( 1 ). (snmjournals.org)
  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. (sfu.ca)
  • Alpha emitter radium-223 and survival in metastatic prostate cancer. (sfu.ca)
  • Targets that have been identified as having the potential to improve survival in patients with castration-resistant prostate cancer stem from research in angiogenesis, bone metabolism, immunotherapy, androgen metabolism and receptor regulation, and apoptosis. (cancernetwork.com)
  • Some of the approaches incorporating these targets have already translated to measurable clinical benefit: sipuleucel-T (Provenge) and cabazitaxel (Jevtana) have demonstrated improvements in median survival of 4.1 and 2.4 months, respectively, in different populations of men with castration-resistant disease. (cancernetwork.com)
  • Since the current gold standard for approval of drugs in castration-resistant prostate cancer is based on overall survival, prospective evaluation of these types of markers as a surrogate for survival is clearly needed, particularly with the plethora of new agents. (cancernetwork.com)
  • Lynparza ® is an oral treatment that has shown improved survival outcomes for patients with the specific gene variants (called BRCA1 or BRCA2) in their prostate cancer. (health.gov.au)
  • On April 29, Janssen announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration (FDA) seeking approval of ERLEADA for the treatment of patients with mCSPC, based upon findings from TITAN, which met its dual primary endpoints, overall survival (OS) and radiographic progression-free survival (rPFS). (jnj.com)
  • The median survival of four years following treatment with PROVENGE is meaningful," said Celestia S. Higano, M.D., FACP, lead author of the PROCEED analysis, and professor, Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center. (gabio.org)
  • Li CE, Chien CS, Chuang YC, Chang YI, Tang HP, Kang CH. Chronic kidneydisease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer. (cgmh.org.tw)
  • Survival rates over 15 years for low-risk prostate cancer were the same whether men chose active surveillance, radiation, or surgery. (everydayhealth.com)
  • Using this technique, it has been shown that the existence of CTCs is a prognostic factor for overall survival in patients with epithelial cancer types, such as breast, colon or prostate cancer ( 11 - 15 ). (iiarjournals.org)
  • Germline genetic testing for pathogenic mutations in people diagnosed with cancer is recommended for several cancer types and has been shown to have a positive effect on survival. (cdc.gov)
Ovarian4
  • Additionally, Lynparza is indicated for the treatment of ovarian cancer , breast cancer , and pancreatic cancer . (empr.com)
  • Ovarian and gastroesophageal cancers are among the most notorious for this sly disease progression, often leading to late-stage diagnoses. (news-medical.net)
  • Indeed, while the risks of breast, ovarian, pancreatic and prostate cancer have been documented for years, recent data show an increased risk of gastric cancer, and suggest an association with lung cancer. (cdc.gov)
  • and family history of some hereditary breast and ovarian cancers. (msdmanuals.com)
Metastases6
  • Several studies have demonstrated an advantage of 68 Ga-PSMA-PET/CT as staging modality for detection of prostate cancer (PCa) metastases. (frontiersin.org)
  • MLN metastases detected by 68 Ga-PSMA-PET/CT seem to be a relevant localization of tumor manifestation and may serve as index lesion in the treatment of recurrent PCa. (frontiersin.org)
  • Previous reports either described MLN metastases of PCa occurring in sentinel lymph node scintigraphy or as a random result during anterior rectal resection in patients with rectal cancer ( 16 - 19 ). (frontiersin.org)
  • Nowadays, a huge body of literature describes CTCs as cells that, after detaching from the primary tumour and circulating through the blood or lymphatic system, are the main cause of the occurrence of metastases in patients with epithelial cancer ( 2 - 4 ). (iiarjournals.org)
  • TTVbone was higher in patients with new extraosseous metastases during 223Ra treatment. (bvsalud.org)
  • The study reported a statistically significant reduction in the development of metastatic disease or prolongation of time to metastases associated with apalutamide compared with placebo (40.5 months vs 16.2 months, respectively). (medscape.com)
Radiotherapy for localized prostate cancer1
  • 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. (sfu.ca)
Immunotherapy2
  • Immunotherapy Combinations for Metastatic Prostate Cancer Despite multiple trials, finding effective combination immunotherapy treatments for metastatic castration resistant prostate cancer remains elusive. (medscape.com)
  • PROVENGE is the only FDA-approved immunotherapy made from a patient's own immune cells for the treatment of prostate cancer. (gabio.org)
Patients with prostate cancer2
  • The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. (stockhouse.com)
  • In a study published this week in Nature Chemistry , the researchers tested the method, called single-cell mRNA cytometry, first on cell lines, and then in a small number samples from patients with prostate cancer, hinting at potential clinical applications in oncology. (genomeweb.com)
Diagnosis7
  • The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. (cua.org)
  • The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. (cua.org)
  • At your initial screening visit, the study team will ask questions about your cancer diagnosis and medical history, perform a physical exam, laboratory tests, CT/MRI scans and electrocardiogram (ECG), and possibly take a biopsy of your tumor. (facingourrisk.org)
  • People with the condition normally have a very good outlook when they receive an early diagnosis and treatment. (medicalnewstoday.com)
  • Ten-Year Distant-Recurrence Risk Prediction in Breast Cancer Learn more about CanAssist Breast -- a novel prognostic test for predicting the risk of breast cancer recurrence ten years after diagnosis. (medscape.com)
  • Black men in the United States are more likely to develop prostate cancer than white men, and after diagnosis, they're more likely to have advanced disease and to die than white men with the disease. (news-medical.net)
  • For additional information please see Prostate Cancer: Diagnosis and Staging , a Critical Images slideshow, to help determine the best diagnostic approach for this potentially deadly disease and/or Advanced Prostate Cancer: Signs of Metastatic Disease , a Critical Images slideshow, for help identifying the signs of metastatic disease. (medscape.com)
Clinical Trials4
  • It covers the Metastatic Castration-Resistant Prostate Cancer pipeline drug profiles, including Metastatic Castration-Resistant Prostate Cancer clinical trials and nonclinical stage products. (giridihjournal.in)
  • Geriatric: This label reflects clinical trials for LEUPROLIDE ACETATE INJECTION DEPOT in prostate cancer in which the majority of the subjects studied were at least 65 years of age. (nih.gov)
  • Translating clinical trials to clinical practice: Outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. (sfu.ca)
  • The article by Ruch and Hussain provides a comprehensive overview of the progress that has been made in translating basic science findings in prostate cancer biology to clinical trials. (cancernetwork.com)
Outcomes5
  • CONCLUSIONS: Analysis of this retrospective cohort suggests that Enz is well tolerated and that there is a 23% response rate in heavily pretreated CRPC patients, which is comparable with third-line treatment outcomes. (ru.nl)
  • There are an estimated 500,000 long-term survivors of childhood cancer in U.S. alone and more than 40% will have been treated with anthracycline-based chemotherapies," said Armenian, who will give an oral presentation of the trial's outcomes on Monday, June 5 , at 9:12 a.m. (wkrn.com)
  • Outcomes After ART in Women With Cancer Does a history of cancer impact outcomes of assisted reproductive technology? (medscape.com)
  • Numerous studies suggest that detection of CTCs in the blood or disseminated tumour cells (DTCs) in the bone marrow of patients with cancer is linked to poor outcomes of the disease and reduced treatment efficiency ( 5 , 6 ). (iiarjournals.org)
  • Understanding how these genomic events impact prognosis and/or treatment response is vital for optimising clinical outcomes. (cdc.gov)
Gastric cancer2
  • Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer. (snpedia.com)
  • From the paper: 'Carriers of pathogenic germline variants (PGV) in BRCA2 could soon be offered gastric cancer screening using gastroscopy. (cdc.gov)
Biopsy8
  • For obvious reasons, and despite their limitations, biopsy and surgical tissue sampling to determine target expression have become the undisputed standard of care in breast and many other cancers. (snmjournals.org)
  • NCCN panel members were divided on the question of PSA thresholds that would prompt prostate biopsy: options include 2.5 ng/mL, 3 ng/mL, or considering the PSA level in the context of other risk factors rather than using a specific PSA cutoff. (medscape.com)
  • Owing to its anatomic location, the prostate may be palpable transrectally and accessed for biopsy via either the rectum or the perineum. (medscape.com)
  • For a more detailed description of prostate biopsy, see Workup/Prostate Biopsy . (medscape.com)
  • Patients whose MRI results are highly suspicious for clinically significant prostate cancer should undergo prostate biopsy. (medscape.com)
  • In this retrospective study, we validate a deep learning-based classifier for prostate cancer (PCA) detection and Gleason grading (AI tool) in biopsy samples. (cdc.gov)
  • Five external cohorts of patients with multifocal prostate biopsy were analyzed from high-volume pathology institutes. (cdc.gov)
  • A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. (lu.se)
Bone6
  • Participants must have ≥ 1 metastatic lesion that is present on magnetic resonance imaging (MRI), computed tomography (CT), or bone scan obtained ≤ 28 days prior to initiation of study treatment. (uclahealth.org)
  • The predominance of patients with metastatic disease in bone has made it difficult to acquire sufficient tissue to perform correlative studies. (cancernetwork.com)
  • The novel dosimetry model was applied to 223Ra-dichloride, frequently used for the treatment of patients with metastatic bone disease from castration-resistant prostate cancer. (lu.se)
  • Study procedures included CT, bone scintigraphy, and 68Ga-PSMA PET/CT at baseline, after 3 and 6 cycles of 223Ra treatment, and on treatment failure. (bvsalud.org)
  • Perhaps the most significant problem to the study, however, is that we now know that CT scan and bone scan will miss a significant number of metastatic sites that can be identified using a PET scan . (medscape.com)
  • The group agreed that [ 177 Lu]Lu-PSMA should not be administered only after progression to cabazitaxel and that [ 223 Ra]RaCl 2 remains a valid therapeutic option in bone-only metastatic castration-resistant PCa. (lu.se)
Locally4
  • Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. (journalsmededu.pl)
  • Cabometyx - a tyrosine kinase inhibitor which prevents cancer cell growth - is an oral tablet that has been approved in the United States to treat several diseases, including advanced renal cell carcinoma, locally advanced or metastatic differentiated thyroid cancer and hepatocellular carcinoma for patients who have previously been treated with Nexavar (sorafenib). (curetoday.com)
  • Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. (sfu.ca)
  • and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. (biospace.com)
Asymptomatic1
  • Most patients presenting with prostate cancer do so with screen-detected cancer and are asymptomatic. (medscape.com)
Stage 4 prostate cancer4
Malignancies2
  • Prostate cancer (PCa) is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). (giridihjournal.in)
  • Risks of Second Non-Breast Primaries Following Breast Cancer A better understanding of the potential risks of developing second primary malignancies among survivors of breast cancer could lead to better prevention and management strategies for these patients. (medscape.com)
Apalutamide3
  • This article presents a case of an elderly patient with internal diseases, who in the castration-resistant stage, was treated with a new generation androgen receptor blocker - apalutamide - in the first line of systemic treatment. (journalsmededu.pl)
  • Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial Lancet Oncol. (journalsmededu.pl)
  • Apalutamide for metastatic, castration-sensitive prostate cancer. (journalsmededu.pl)
Testosterone5
CRPC2
  • Over the past decade, the treatment landscape in metastatic castration-resistant prostate cancer (CRPC) has markedly changed, with the introduction of three new chemotherapeutic agents. (touchoncology.com)
  • The androgen signaling pathway has recently been found to be critical in both hormone-sensitive prostate cancer and CRPC. (touchoncology.com)
Progression3
  • Treatment continued until disease progression. (jhoponline.com)
  • Preventing or delaying radiographic progression is an important clinical endpoint in assessing cancer treatment and is very important to patients, their caregivers and their families," said Andrew Armstrong, MD, ScM, Duke Cancer Institute, Durham, N.C. and an investigator in the trial. (empr.com)
  • Nature Medicine asks six leading AI researchers to explain how LLM-powered chatbots are having an impact on health, from virtual nurses to detecting cancer progression. (nature.com)
Cabazitaxel3
  • citation needed] Cabazitaxel was developed by Sanofi-Aventis and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in June 2010. (wikipedia.org)
  • Cabazitaxel is indicated in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer following docetaxel-based treatment. (wikipedia.org)
  • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. (sfu.ca)
PSMA12
  • Upon binding to PSMA on the surface of cancer cells, ARX517 is internalized and pAF-AS269, its cancer cell killing payload, is released following lysosomal metabolism. (ambrx.com)
  • In June 2022, Blue Earth Therapeutics announced results from a series of preclinical analyses designed to evaluate the biodistribution and potential therapeutic efficacy of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in the treatment of prostate cancer preclinical models. (giridihjournal.in)
  • Eight of these patients received a follow-up 68 Ga-PSMA-PET/CT to evaluate treatment response and further evolution. (frontiersin.org)
  • Given the high prevalence of PSMA expression in advanced prostate cancer and the PSMA PET screening positivity rate of 87% in the VISION trial, some have argued that the trial could have been positive even in an unselected population ( 2 ). (snmjournals.org)
  • The prevalence of PSMA expression is more than 90% in prostate cancer ( 3 - 6 ). (snmjournals.org)
  • Lesions with low PSMA expression and high glycolytic activity (PSMA-negative/ 18 F-FDG-positive) can occur in up to 30% of metastatic castration-resistant prostate cancer patients referred for PSMA-targeted MRT ( 14 , 15 ). (snmjournals.org)
  • At the Peter MacCallum Cancer Centre, Australia, patients are routinely selected for PSMA-targeted MRT by PSMA and 18 F-FDG PET. (snmjournals.org)
  • On the basis of these data and our own experience, not characterizing target expression before PSMA-targeted treatment appears as nonsensical as omitting breast cancer receptor phenotyping from the standard work-up of breast cancer patients. (snmjournals.org)
  • Figure 1 depicts a patient with low-PSMA-expressing disease and a poor subsequent treatment response. (snmjournals.org)
  • PSMA PET/CT of patient with metastatic castration-resistant prostate cancer before treatment with 177 Lu-PSMA therapy. (snmjournals.org)
  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. (thieme-connect.de)
  • For 68Ga-PSMA PET/CT, TTVbone at baseline was lower in good responders than in poor responders, whereas TTVbone increased in both groups during treatment. (bvsalud.org)
Therapy19
  • The basic method of treatment in patients with advanced prostate cancer is androgen deprivation therapy, however, over time, the tumor evolves into a castration-resistant form, which poses a significant threat to the patient's life. (journalsmededu.pl)
  • 10. Desai K, McManus JM, Sharifi N. Hormonal Therapy for Prostate Cancer. (journalsmededu.pl)
  • It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy. (wikipedia.org)
  • The trial was double-blinded, meaning participants and doctors don't know which therapy is received until the trial is over, creating less bias, and placebo-controlled, which refers to a group of participants receiving a treatment that has no active properties. (wkrn.com)
  • Reflections on Treatment for Endometriosis-associated Pain The authors discuss the pros and cons of surgery vs. hormonal therapy for treatment of endometriosis-associated pain, focusing on the role of patient fears and misunderstanding. (medscape.com)
  • Another hematologic or solid tumor ≥ stage 1 malignancy that completed surgery, last dose of radiotherapy, or last dose of systemic anti-cancer therapy ≤ 2 years from first dose of study treatment. (uclahealth.org)
  • Participants who had curative therapy for non-melanomatous skin cancer or for localized malignancy are eligible. (uclahealth.org)
  • Tecentriq is an immune checkpoint inhibitor, which is a type of targeted therapy drug, and is also considered a monoclonal antibody that binds to the protein PD-L1 on the surface of certain cancer cells, preventing the cancer cells from suppressing the immune system, as noted from the National Cancer Institute. (curetoday.com)
  • Prior treatment with radioligand therapy including other lutetium-labeled compounds. (orlandohealth.com)
  • Are we able to correctly identify prostate cancer patients who could be adequately treated by focal therapy? (urotoday.com)
  • Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. (sfu.ca)
  • Our agreement with Bavarian Nordic reflects our commitment to following the emerging science in immuno-oncology and supports our strategy to transform the treatment of cancer across multiple tumor types, lines of therapy and stages of disease. (centerwatch.com)
  • Radiotheranostics are small-molecule or carrier-bound radiopharmaceuticals that can be used for diagnostic imaging and radionuclide therapy, especially for the treatment of various tumour diseases. (thieme-connect.de)
  • Guidelines for radioiodine therapy of differentiated thyroid cancer. (thieme-connect.de)
  • Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. (thieme-connect.de)
  • Hormone therapy, also known as androgen deprivation therapy (ADT), has long been the key treatment for metastatic prostate cancer. (everydayhealth.com)
  • Emerging treatments with limited long-term data include targeted therapy and whole-gland ablation. (medscape.com)
  • Prostate cancer may recur in up to a third of men after definitive local therapy. (medscape.com)
  • Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer. (cdc.gov)
Oncology7
  • Prostate cancer, Version 2.2019, NCCN clinical practice guidelines in oncology. (journalsmededu.pl)
  • More than 40,000 oncology professionals and others will attend the conference, or join virtually, to learn about the latest scientific research on cancer treatment, detection and prevention. (wkrn.com)
  • The Emerging Role for CAR T Cells in Solid Tumor Oncology Learn more about the exciting potential role of CAR T cells in the targeted treatment of solid tumor cancers. (medscape.com)
  • While additional treatment options have become available, metastatic castration-resistant prostate cancer remains largely incurable," said Michael Giordano, head of development, oncology, Bristol-Myers Squibb. (centerwatch.com)
  • Bristol-Myers Squibb has an ongoing phase III program for YERVOY in prostate cancer, and scientific rationale exists to evaluate PROSTVAC in combination with YERVOY, and other agents from Bristol-Myers Squibb's immuno-oncology portfolio. (centerwatch.com)
  • As we continue to advance our portfolio and pipeline, we are pleased to present important new findings for ERLEADA in metastatic castration-sensitive prostate cancer, and for DARZALEX in the treatment of newly diagnosed multiple myeloma and as a subcutaneous formulation," said Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC. (jnj.com)
  • Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. (gurufocus.com)
Prostatic3
Recurrent2
  • Here, due to limited sensitivity and specificity conventional imaging methods, such as computed tomography (CT) and magnetic resonance imaging (MRI), might struggle to accurately determine the presence or absence of metastatic or recurrent PCa ( 4 , 5 ). (frontiersin.org)
  • Increasingly discussed salvage treatment of recurrent PCa also demands exact staging ( 4 , 10 , 12 , 13 ). (frontiersin.org)
Refractory2
  • Beleodaq is indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma. (pharmaceutical-technology.com)
  • Findings from the Phase 3 COLUMBA study will be presented ( Abstract #8005 ) evaluating the subcutaneous formulation in the treatment of patients with relapsed or refractory multiple myeloma. (jnj.com)
Mitoxantrone1
  • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (sfu.ca)
Detection1
Tumor growth2
  • Androgens are male hormones that can promote tumor growth in the prostate gland. (drugs.com)
  • The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer. (lu.se)
Methylprednisolone1
  • Zytiga is used together with steroid medication ( prednisone or methylprednisolone ) to treat prostate cancer that has spread to other parts of the body. (drugs.com)
Abstract2
  • From the abstract: ' Do rare pathogenic variants in genes beyond previously established prostate cancer risk genes contribute to risk of aggressive prostate cancer? (cdc.gov)
  • From the abstract: 'Do disparities exist in the application of precision medicine for Black and White men with metastatic prostate cancer? (cdc.gov)
Androgen suppression2
  • External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. (journalsmededu.pl)
  • Duration of androgen suppression in the treatment of prostate cancer. (sfu.ca)
Therapies6
  • ASCO 2019: A Phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350). (larvol.com)
  • Over 75+ Metastatic Castration-Resistant Prostate Cancer companies are evaluating 75+ Metastatic Castration-Resistant Prostate Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the Metastatic Castration-Resistant Prostate Cancer market would significantly increase market revenue. (giridihjournal.in)
  • To date, there have been no effective therapies to prevent heart failure in long-term childhood cancer survivors who have been treated with anthracyclines. (wkrn.com)
  • With prostate cancer confirmed as the second most commonly occurring cancer in men globally, the need for innovative new therapies is extensive, especially for those whose cancer has progressed to the metastatic castration-resistant form," said Howard Mayer, executive vice president and head of research and development at Ipsen, in the press release. (curetoday.com)
  • Cedars-Sinai Cancer investigators have found that Black men respond as well as white men to systemic therapies for advanced prostate cancer when access to quality healthcare is equal, regardless of socioeconomic status. (news-medical.net)
  • Translational research on prostate cancer: Identification of molecular targets for development of new therapies in chemo- and hormone resistant prostate cancer. (lu.se)
Variants5
  • Genetic variants and prostate cancer risk: candidate replication and exploration of viral restriction genes. (snpedia.com)
  • Lynparza ® (olaparib) will be extended on the PBS to include the treatment of metastatic castration‑resistant prostate cancer in patients with specific pathogenic gene variants. (health.gov.au)
  • Gene variants in a patient's cancer are confirmed by laboratory testing. (health.gov.au)
  • In a comprehensive multi-ancestry GWAS meta-analysis, researchers identified 451 risk variants for prostate cancer, including 187 new variants, demonstrating the utility of such studies across diverse populations. (news-medical.net)
  • The findings of this study suggest that DNA repair and cancer susceptibility genes can inform disease management in men with nonaggressive prostate cancer, as men carrying deleterious variants in these genes are likely to develop advanced disease. (cdc.gov)
Prognostic1
  • A prognostic model for invasive breast cancer that is based on interpretable measurements of epithelial, stromal, and immune components outperforms histologic grading by expert pathologists. (nature.com)
Findings2
  • These positive findings from CONTACT-02 are highly encouraging given the need for additional, non-cytotoxic or non-chemotherapeutic treatment options for this patient population," Dr. Neeraj Agarwal, professor and presidential endowed chair of cancer research at Huntsman Cancer Institute, University of Utah and the global lead investigator of the trial, said in the press release. (curetoday.com)
  • These findings suggest that although precision medicine in metastatic prostate cancer has become more common, opportunities remain to improve access to precision medicine to benefit Black men with prostate cancer. (cdc.gov)
Hereditary3
  • Sign Up for FORCE Newsletters to stay up-to-date on hereditary cancer news, research, support, advocacy and clinical trial information. (facingourrisk.org)
  • What is your primary connection to hereditary cancer? (facingourrisk.org)
  • Your information is used for the sole purpose of sending information about hereditary cancer and updates on FORCE programs and campaigns. (facingourrisk.org)
Disease9
  • Prostate cancer continues to be a leading cause of cancer-related death worldwide and is the most common malignancy among American men after skin cancer.1 Based on estimates by the American Cancer Society, approximately 241,740 new cases are expected to be diagnosed and 28,170 men are expected to die from the disease in the US in 2012. (touchoncology.com)
  • However, this population may still respond to secondary hormonal manipulations and ADT continues to be the gold standard for systemic treatment of men with metastatic disease. (touchoncology.com)
  • Thus, after a seven-year drought following the approval of docetaxel (Taxotere)/prednisone, we are experiencing a windfall in new treatments for a disease that only ten years ago was considered untreatable. (cancernetwork.com)
  • The Morrison Government is also listing additional important and lifesaving drugs on the PBS from today, including for Australians with asthma, prostate cancer, Castleman disease, Human Immunodeficiency Virus (HIV) and Crohn's disease. (health.gov.au)
  • The final analysis with six years of follow-up continues to support long-term disease control and tolerability with IMBRUVICA in the treatment of CLL/SLL. (jnj.com)
  • Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. (gurufocus.com)
  • A decrease in ALP, which occurred in most patients, was not correlated with a decrease in TTVbone, which might make one question the value of ALP for disease monitoring during 223Ra treatment in clinical practice. (bvsalud.org)
  • The NCCN recommends performing a baseline history (including family history, medications, and any history of prostate screening and disease) and physical examination. (medscape.com)
  • Patient summary: There are situations when dealing with prostate cancer (PCa) where both the doctors who diagnose and track the disease development and response to treatment, and those who give treatments are unsure about what the best course of action is. (lu.se)
Breast cancers1
  • Approximately 20% of breast cancers express human epidermal growth factor receptor 2 (Erb-B2 receptor tyrosine kinase 2 [ERBB2], formerly HER2), and 70% express estrogen or progesterone receptors. (snmjournals.org)
Screening7
  • Mortality results from a randomized prostate-cancer screening trial. (sfu.ca)
  • Screening and prostate cancer mortality: Results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. (sfu.ca)
  • The guidelines agree that PSA-based prostate cancer screening requires an informed, shared decision-making process, and that the decision should reflect the patient's understanding of the possible benefits and risks and should respect the patient's preferences and values. (medscape.com)
  • Multiple institutions and collaborative groups have addressed prostate cancer screening. (medscape.com)
  • The United States Preventive Services Task Force (USPSTF) recomended against prostate cancer screening in 2011-2012, but in 2018 reversed the recommendation to include screening after an informed discussion. (medscape.com)
  • The evidence for and against screening, a summary of screening guidelines, and the observed impact of the USPSTF guidelines on prostate cancer incidence and mortality are presented in full detail in Workup/Prostate Cancer Screening . (medscape.com)
  • In the longer term, some might even take part in lung cancer screening programs. (cdc.gov)
Inhibitor2
  • Participants with known BRCA or ATM mutation (germline or somatic) are not eligible unless they received prior treatment with a PARP inhibitor where available, indicated and tolerated. (uclahealth.org)
  • In the SIMPLIFY-1 multicenter, randomized, double-blind, phase III study, safety and efficacy of momelotinib was compared with ruxolitinib in 432 patients with myelofibrosis who had not received prior treatment with a JAK inhibitor. (medscape.com)
Biopsies2
  • False-negative results often occur, so multiple biopsies may be needed before prostate cancer is detected. (medscape.com)
  • Pathologic examination of prostate biopsies is time consuming due to the large number of slides per case. (cdc.gov)
Mortality3
  • Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. (journalsmededu.pl)
  • Early Mortality in ICI-Treated Cancers in Routine Practice A better understanding of the predictors of early mortality among cancer patients treated with ICIs could help guide treatment selection. (medscape.com)
  • Delayed testing and less access to tailored, advanced treatments drive higher mortality rates for Black men with prostate cancer compared to other men. (everydayhealth.com)